Human Molecular Genetics, 2002, Vol. 11, No. 20 2517-2530
© 2002 Oxford University Press
Pharmacogenomics in schizophrenia: the quest for individualized therapy
1Neurogenetics Section, Centre for Addiction and Mental Health (CAMH), Clarke Division, University of Toronto, Toronto, Canada and 2Department of Psychiatry, University of California, Irvine, USA
Received August 7, 2002; Accepted August 22, 2002
There is strong evidence to suggest that genetic variation plays an important role in inter-individual differences in medication response and toxicity. The rapidly evolving disciplines of pharmacogenetics and pharmacogenomics seek to uncover this genetic variation in order to predict treatment outcomes. The goal is to be able to select the drugs with the greatest likelihood of benefit and the least likelihood of harm in individual patients, based on their genetic make-up—individualized therapy. Pharmacogenomic studies utilize genomic technologies to identify chromosomal areas of interest and novel putative drug targets, while pharmacogenetic strategies rely on studying sequence variations in candidate genes suspected of affecting drug response or toxicity. The candidate gene variants that affect function of the gene or its protein product have the highest priority for investigation. This review will provide demonstrative examples of functional candidate gene variants studied in a variety of antipsychotic response phenotypes in the treatment of schizophrenia. Serotonin and dopamine receptor gene variants in clozapine response will be examined, and in the process the need for sub-phenotypes will be pointed out. Our recent pharmacogenetic studies of the subphenotype of neurocognitive functioning following clozapine treatment and the dopamine D1 receptor gene (DRD1) will be presented, highlighting our novel neuroimaging data via [18F]fluoro-2-deoxy-D-glucose (FDG) metabolism position emission tomography (PET) that demonstrates hypofunctioning of several brain regions in patients with specific dopamine D1 genotype. Preliminary candidate gene studies investigating the side-effect of clozapine-induced weight gain are also presented. The antipsychotic adverse reaction of tardive dyskinesia and its association with the dopamine D3 receptor will be critically examined, as well as the added influence of antipsychotic metabolism via the cytochrome P450 1A2 gene (CYP1A2 ) . Results that delineate the putative gene–gene interaction between DRD3 and CYP1A2 are also presented. We have also utilized FDG–PET subphenotyping to demonstrate increased brain region activity in patients who have the dopamine D3 genotype that confers increased risk for antipsychotic induced tardive dyskinesia. The merits and weaknesses of neuroimaging technologies as applied to pharmacogenetic analyses are discussed. To the extent that the above data become more widely verified and replicated, the field of psychiatry will move closer to clinically meaningful tests that will be useful in deciding the best drug for each individual patient.
* To whom correspondence should be addressed at: Neurogenetics Section, R-31, Clarke Site, Centre for Addiction and Mental Health (CAMH), 250 College Street, Toronto, Ontario, Canada M5T 1R8. Tel: +1 4169794987; Fax: +1 4169794666; Email: james_kennedy{at}camh.net, vincebasile{at}ica.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B Wilffert, A. Al Hadithy, V. Sing, G Matroos, H. Hoek, J van Os, R Bruggeman, J. Brouwers, and P. van Harten The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX J Psychopharmacol, August 1, 2009; 23(6): 652 - 659. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Founds Introducing Systems Biology for Nursing Science Biol Res Nurs, July 1, 2009; 11(1): 73 - 80. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Leckband, J. R. Bishop, and V. L. Ellingrod Pharmacogenomics in Psychiatry Journal of Pharmacy Practice, June 1, 2007; 20(3): 252 - 264. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Lencer, G. Eismann, M. Kasten, K. Kabakci, V. Geithe, J. Grimm, and C. Klein Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms The British Journal of Psychiatry, December 1, 2004; 185(6): 465 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L Halliday, V. R Collins, M. A. Aitken, M. P M Richards, and C. A Olsson Genetics and public health--evolution, or revolution? J Epidemiol Community Health, November 1, 2004; 58(11): 894 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Tsapakis, A. Basu, and K. J. Aitchison Clinical relevance of discoveries in psychopharmacogenetics Adv. Psychiatr. Treat., November 1, 2004; 10(6): 455 - 465. [Abstract] [Full Text] [PDF]
|
|